Printer Friendly
The Free Library
19,607,059 articles and books
Member login
User name  
Password 
 
Join us Forgot password?

Biovail Announces Third-Quarter 2009 Earnings Release, Conference-Call Details.


TORONTO -- Biovail Corporation (NYSE NYSE

See: New York Stock Exchange
:BVF BVF Biovail Corporation (stock symbol)
BVF Berufsverband der Frauenärzte eV (Muenchen, Germany)
BVF Bearing Versus Frequency
) (TSX TSX Toronto Stock Exchange (TSE before April, 2002)
TSX Transfer from Stack Pointer to Index
TSX True Space Extension
:BVF) today announced that it will host a conference call and webcast on Thursday, November 5, 2009 at 8:30a.m. for Company executives to discuss third-quarter 2009 financial and operational results.

Following the discussion, Biovail executives will address inquiries from investment analysts.

A live webcast of this call will be available through the Investor Relations Investor relations

The process by which the corporation communicates with its investors.
 section of Biovail's website at www.biovail.com. To access the call live, please dial 416-340-8427 (Toronto and International callers) and 1-866-225-2055 (U.S. and Canada). Listeners are encouraged to dial in 10 minutes before the call begins to avoid delays.

A replay of the conference call will be available until 7:00p.m. ET on Thursday, November 12, 2009 by dialing 416-695-5800 (Toronto and International callers) and 1-800-408-3053 (U.S. and Canada), using access code: 2777843#.

About Biovail Corporation

Biovail Corporation is a specialty pharmaceutical company engaged in the formulation, clinical testing, registration, manufacture, and commercialization of pharmaceutical products. The Company is focused on the development and commercialization of medicines that address unmet un·met  
adj.
Not satisfied or fulfilled: unmet demands. 
 medical needs in niche specialty central nervous system (CNS See Continuous net settlement.

CNS

See continuous net settlement (CNS).
) markets. For more information about Biovail, visit the Company's Web site at www.biovail.com.

For further information, please contact Nelson F. Isabel at 905-286-3000 or send inquiries to ir@biovail.com.
COPYRIGHT 2009 Business Wire
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2009 Gale, Cengage Learning. All rights reserved.

 Reader Opinion

Title:

Comment:



 

Article Details
Printer friendly Cite/link Email Feedback
Publication:Business Wire
Article Type:Financial report
Geographic Code:1CONT
Date:Oct 23, 2009
Words:217
Previous Article:The Medicines Company Announces Positive CHMP Opinion for Angiox[R] (Bivalirudin) for Use in Heart Attack Patients Undergoing Emergency Heart...
Next Article:Atrinsic, Inc. Announces Receipt of Notice from NASDAQ.
Topics:



Related Articles
BIOVAIL PROVIDES 2005 GUIDANCE AND STRATEGY UPDATE.
Biovail Reports First-Quarter 2006 Financial Results; Company Records Total Revenues of $220.5 Million; Operating Margins of 35.1%; EPS From...
Biovail Reports First-Quarter 2008 Financial Results.
Biovail Announces Fourth-Quarter 2008 Earnings Release, Conference-Call Details.
Biovail Announces First-Quarter 2009 Earnings Release, Conference-Call Details.
Biovail Reports First-Quarter 2009 Financial Results.
Biovail Announces Second-Quarter 2009 Earnings Release, Conference-Call Details.
Biovail Reports Second-Quarter 2009 Financial Results.
Biovail Reports Third-Quarter 2009 Financial Results.
ACADIA Pharmaceuticals Reports Third Quarter 2009 Financial Results.

Terms of use | Copyright © 2012 Farlex, Inc. | Feedback | For webmasters | Submit articles